List of Jaypirca drug patents
Jaypirca is owned by Loxo Oncol.
Jaypirca contains Pirtobrutinib.
Jaypirca has a total of 4 drug patents out of which 0 drug patents have expired.
Jaypirca was authorised for market use on 27 January, 2023.
Jaypirca is available in tablet;oral dosage forms.
Jaypirca can be used as treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor.
Drug patent challenges can be filed against Jaypirca from 2027-01-27.
The generics of Jaypirca are possible to be released after 16 December, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 27, 2030 |
| New Chemical Entity Exclusivity (NCE) | Jan 27, 2028 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 2027-01-27
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic